Company Overview

Cybin Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health disorders. The company operates within the biotechnology and neuropsychiatric drug development industries, with a primary emphasis on treatments for conditions such as major depressive disorder, generalized anxiety disorder, and other psychiatric illnesses with significant unmet medical need. Cybin’s core strategy centers on combining proprietary psychedelic compounds with drug delivery technologies and therapeutic support protocols intended to improve efficacy, dosing consistency, and patient experience. Its principal value drivers are its investigational drug candidates, intellectual property portfolio, and clinical development pipeline.

The company was founded in 2019 and is headquartered in Toronto, Canada, with operational and research activities extending into the United States and other international markets. Cybin evolved from an early-stage psychedelic research company into a publicly traded clinical biotechnology organization through acquisitions, licensing arrangements, and internal drug development efforts. The company has sought to differentiate itself through shorter-duration psychedelic compounds, novel deuterated molecules, and controlled treatment protocols designed to improve scalability and commercial viability relative to earlier psychedelic-assisted therapy models.

Business Operations

Cybin generates value primarily through the advancement of proprietary therapeutic candidates and related intellectual property. Its operations are centered on clinical research, preclinical development, regulatory engagement, and strategic collaborations. The company’s lead programs include CYB003, a deuterated psilocybin analog being evaluated for major depressive disorder, and CYB004, a proprietary deuterated dimethyltryptamine (DMT) program targeting anxiety disorders. Cybin also maintains a portfolio of formulation technologies, drug delivery systems, and patents intended to support long-term commercialization opportunities.

Operationally, Cybin maintains activities across both North America and selected international jurisdictions through research partnerships, contract research organizations, and clinical trial sites. The company has collaborated with academic institutions and specialized pharmaceutical development partners to support drug discovery, toxicology studies, and clinical execution. Cybin previously expanded its technology and intellectual property capabilities through acquisitions including Adelia Therapeutics Inc. and licensing agreements related to psychedelic molecule engineering and delivery technologies.

Strategic Position & Investments

Cybin’s strategic direction is focused on advancing regulated psychedelic therapeutics through late-stage clinical development while building a defensible intellectual property estate. The company has invested heavily in clinical trials, regulatory preparation, and next-generation molecule design intended to improve treatment duration, pharmacokinetics, and patient accessibility. Its strategy reflects broader industry trends toward integrating psychedelic compounds into evidence-based psychiatric care under supervised medical frameworks.

The company has pursued growth through acquisitions, licensing arrangements, and capital market financing. Notable transactions include the acquisition of Adelia Therapeutics Inc., which expanded Cybin’s discovery platform and intellectual property assets. Cybin has also invested in proprietary deuteration technologies and formulation methods intended to create differentiated compounds with potentially improved therapeutic profiles. The company operates within the emerging psychedelic medicine sector alongside other clinical-stage biotechnology firms pursuing FDA-regulated psychiatric therapies.

Geographic Footprint

Cybin is headquartered in Toronto, Ontario, and maintains a significant operational presence in the United States, where much of its clinical development activity and regulatory engagement occurs. The company’s research and clinical programs involve partnerships and trial sites across multiple regions, including parts of North America and selected international markets involved in psychedelic research and pharmaceutical development.

Its market and investment focus is primarily concentrated in the United States and Canada, reflecting the importance of U.S. regulatory approval pathways and North American capital markets for biotechnology funding. Cybin’s international operational influence is largely tied to cross-border clinical research collaborations, intellectual property development, and partnerships supporting pharmaceutical innovation in mental health therapeutics.

Leadership & Governance

Cybin’s leadership team is composed of executives with backgrounds in biotechnology, pharmaceuticals, capital markets, and mental health research. The company’s governance approach emphasizes clinical rigor, regulatory compliance, intellectual property development, and long-term advancement of psychedelic therapeutics within established healthcare systems. Public communications and corporate filings consistently position the company around evidence-driven psychiatric treatment innovation and disciplined clinical execution.

Key executives include:

• Doug Drysdale – Chief Executive Officer
• Paul Glavine – Chief Financial Officer
• Dr. Amir Inamdar – Chief Medical Officer
• Eric So – Chief Information Officer
• Alex Belser, Ph.D. – Chief Clinical Officer

Cybin’s leadership has emphasized advancing proprietary psychedelic compounds through controlled clinical pathways, strengthening patent protections, and building strategic partnerships intended to support future commercialization and regulatory acceptance.